PET of Hypoxia with 89Zr-Labeled cG250-F(ab′)2 in Head and Neck Tumors
暂无分享,去创建一个
B. Hoeben | W. Oyen | J. Bussink | J. Kaanders | E. Troost | E. Oosterwijk | O. Boerman | G. Franssen | P. Rijken | G. V. Dongen | G. Dongen
[1] A. Scott,et al. Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and ¹²⁴I-cG250 PET/CT. , 2011, Urologic oncology.
[2] J. Kaanders,et al. Hypoxia in larynx carcinomas assessed by pimonidazole binding and the value of CA-IX and vascularity as surrogate markers of hypoxia. , 2009, European journal of cancer.
[3] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[4] G. V. van Dongen,et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[5] U. Qureshi,et al. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours , 2009, British Journal of Cancer.
[6] Martin Gotthardt,et al. Spatial Resolution and Sensitivity of the Inveon Small-Animal PET Scanner , 2008, Journal of Nuclear Medicine.
[7] J. Bussink,et al. Molecular aspects of tumour hypoxia , 2008, Molecular oncology.
[8] J. Bussink,et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. , 2008, International journal of radiation oncology, biology, physics.
[9] J. Humm,et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.
[10] W. Oyen,et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] Y. Yonekura,et al. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. , 2006, Nuclear medicine and biology.
[12] P. D. de Wilde,et al. The prognostic value of endogenous hypoxia-related markers for head and neck squamous cell carcinomas treated with ARCON. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[13] J. Bowsher,et al. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] A. Harris,et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Bussink,et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[16] J. Bussink,et al. Hypoxic cell turnover in different solid tumor lines. , 2005, International journal of radiation oncology, biology, physics.
[17] C. Supuran,et al. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. , 2005, Journal of medicinal chemistry.
[18] C Clifton Ling,et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor mo , 2005, International journal of radiation oncology, biology, physics.
[19] Søren M Bentzen,et al. Theragnostic imaging for radiation oncology: dose-painting by numbers. , 2005, The Lancet. Oncology.
[20] W. Oyen,et al. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. , 2004, Cancer biotherapy & radiopharmaceuticals.
[21] Johan Bussink,et al. Clinical studies of hypoxia modification in radiotherapy. , 2004, Seminars in radiation oncology.
[22] R. Boellaard,et al. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] C. Sweep,et al. Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome , 2003, British Journal of Cancer.
[24] A. Harris,et al. GLUT‐1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: Relationship to pimonidazole binding , 2003, International journal of cancer.
[25] Johan Bussink,et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.
[26] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[27] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[28] J. Bussink,et al. Optical Sensor-Based Oxygen Tension Measurements Correspond with Hypoxia Marker Binding in Three Human Tumor Xenograft Lines , 2000, Radiation research.
[29] R J Hodgkiss,et al. Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. , 2000, International journal of radiation oncology, biology, physics.
[30] R. Brakenhoff,et al. Molecular cloning and immunogenicity of renal cell carcinoma‐associated antigen G250 , 2000, International journal of cancer.
[31] E. T. Gawlinski,et al. A reaction-diffusion model of cancer invasion. , 1996, Cancer research.
[32] R. Kettmann,et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. , 1996, Genomics.
[33] P. Kenemans,et al. Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice. , 1991, Anticancer research.
[34] G. Fleuren,et al. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinity , 1991, International journal of cancer.
[35] D. Ruiter,et al. Monoclonal antibody G 250 recognizes a determinant present in renal‐cell carcinoma and absent from normal kidney , 1986, International journal of cancer.
[36] J N Weinstein,et al. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. , 1986, Cancer research.
[37] P. Bunn,et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.
[38] S. Pastoreková,et al. Tumor-associated carbonic anhydrases and their clinical significance. , 2006, Advances in clinical chemistry.
[39] L. Khawli,et al. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody. , 2003, Cancer biotherapy & radiopharmaceuticals.
[40] Michael Unser,et al. A pyramid approach to subpixel registration based on intensity , 1998, IEEE Trans. Image Process..